Literature DB >> 19172225

Inhibition of the classical NF-kappaB pathway prevents osteoclast bone-resorbing activity.

Niroshani S Soysa1, Neil Alles, Hitoyata Shimokawa, Eijiro Jimi, Kazuhiro Aoki, Keiichi Ohya.   

Abstract

The classical NF-kappaB pathway plays an important role in osteoclast formation and differentiation; however, the role of NF-kappaB in osteoclast bone-resorbing activity is not well understood. To elucidate whether NF-kappaB is important for osteoclast bone-resorbing activity, we used a selective peptide inhibitor of the classical NF-kappaB pathway named the NBD peptide. Osteoclasts were generated using bone marrow macrophages in the presence of M-CSF and RANKL. The NBD peptide dose-dependently blocked the bone-resorbing activity of osteoclasts by reducing area, volume (p < 0.001) and depths (p < 0.05) of pits. The reduced resorption by the peptide was due to reduced osteoclast bone-resorbing activity, but not reduced differentiation as the number of osteoclasts was similar in all groups. The peptide inhibited bone resorption by reducing TRAP activity, disrupting actin rings and preventing osteoclast migration. Gene expressions of a panel of bone resorption markers were significantly reduced. The NBD peptide dose-dependently reduced the RANKL-induced c-Src kinase activity, which is important for actin ring formation and osteoclast bone resorption. Therefore, these data suggest that the classical NF-kappaB pathway plays a pivotal role in osteoclast bone-resorbing activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19172225     DOI: 10.1007/s00774-008-0026-6

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  38 in total

Review 1.  Alternative pathways of NF-kappaB activation: a double-edged sword in health and disease.

Authors:  Gutian Xiao; Arnold B Rabson; Wise Young; Guoliang Qing; Zhaoxia Qu
Journal:  Cytokine Growth Factor Rev       Date:  2006-06-21       Impact factor: 7.638

2.  Tyrosine phosphorylation of p130Cas is involved in actin organization in osteoclasts.

Authors:  I Nakamura; E Jimi; L T Duong; T Sasaki; N Takahashi; G A Rodan; T Suda
Journal:  J Biol Chem       Date:  1998-05-01       Impact factor: 5.157

3.  A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss.

Authors:  Kazuhiro Aoki; Hiroaki Saito; Cecile Itzstein; Masaji Ishiguro; Tatsuya Shibata; Roland Blanque; Anower Hussain Mian; Mariko Takahashi; Yoshifumi Suzuki; Masako Yoshimatsu; Akira Yamaguchi; Pierre Deprez; Patrick Mollat; Ramachandran Murali; Keiichi Ohya; William C Horne; Roland Baron
Journal:  J Clin Invest       Date:  2006-05-04       Impact factor: 14.808

4.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

Authors:  Hiroshi Takayanagi; Sunhwa Kim; Takako Koga; Hiroshi Nishina; Masashi Isshiki; Hiroki Yoshida; Akio Saiura; Miho Isobe; Taeko Yokochi; Jun-ichiro Inoue; Erwin F Wagner; Tak W Mak; Tatsuhiko Kodama; Tadatsugu Taniguchi
Journal:  Dev Cell       Date:  2002-12       Impact factor: 12.270

5.  Regulation of osteoclast differentiation and function by the CaMK-CREB pathway.

Authors:  Kojiro Sato; Ayako Suematsu; Tomoki Nakashima; Sayaka Takemoto-Kimura; Kazuhiro Aoki; Yasuyuki Morishita; Hiroshi Asahara; Keiichi Ohya; Akira Yamaguchi; Toshiyuki Takai; Tatsuhiko Kodama; Talal A Chatila; Haruhiko Bito; Hiroshi Takayanagi
Journal:  Nat Med       Date:  2006-11-26       Impact factor: 53.440

6.  Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1.

Authors:  Masahito Matsumoto; Masakazu Kogawa; Seiki Wada; Hiroshi Takayanagi; Masafumi Tsujimoto; Shigehiro Katayama; Koji Hisatake; Yasuhisa Nogi
Journal:  J Biol Chem       Date:  2004-08-09       Impact factor: 5.157

7.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice.

Authors:  P Soriano; C Montgomery; R Geske; A Bradley
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

8.  Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone.

Authors:  I Nakamura; M F Pilkington; P T Lakkakorpi; L Lipfert; S M Sims; S J Dixon; G A Rodan; L T Duong
Journal:  J Cell Sci       Date:  1999-11       Impact factor: 5.285

Review 9.  Molecular regulation of osteoclast activity.

Authors:  Angela Bruzzaniti; Roland Baron
Journal:  Rev Endocr Metab Disord       Date:  2006-06       Impact factor: 9.306

10.  The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

Authors:  T L Burgess; Y Qian; S Kaufman; B D Ring; G Van; C Capparelli; M Kelley; H Hsu; W J Boyle; C R Dunstan; S Hu; D L Lacey
Journal:  J Cell Biol       Date:  1999-05-03       Impact factor: 10.539

View more
  18 in total

1.  Activation of EPAC1/2 is essential for osteoclast formation by modulating NFκB nuclear translocation and actin cytoskeleton rearrangements.

Authors:  Aránzazu Mediero; Miguel Perez-Aso; Bruce N Cronstein
Journal:  FASEB J       Date:  2014-08-13       Impact factor: 5.191

2.  A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.

Authors:  Francois Lamoureux; Christian Thomas; Min-Jean Yin; Hidetoshi Kuruma; Ladan Fazli; Martin E Gleave; Amina Zoubeidi
Journal:  Clin Cancer Res       Date:  2011-02-24       Impact factor: 12.531

3.  NF-κB inhibition protects against tumor-induced cardiac atrophy in vivo.

Authors:  Ashley Wysong; Marion Couch; Scott Shadfar; Luge Li; Lugi Li; Jessica E Rodriguez; Scott Asher; Xiaoying Yin; Mitchell Gore; Al Baldwin; Cam Patterson; Monte S Willis
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

4.  A simple and robust reporter gene assay for measuring the bioactivity of anti-RANKL therapeutic antibodies.

Authors:  Chuanfei Yu; Lan Wang; Yongbo Ni; Junzhi Wang
Journal:  RSC Adv       Date:  2019-12-03       Impact factor: 4.036

5.  Ubiquitin-like domain of IKKβ regulates osteoclastogenesis and osteolysis.

Authors:  Yanhong Zhang; Jesse E Otero; Yousef Abu-Amer
Journal:  Calcif Tissue Int       Date:  2013-05-18       Impact factor: 4.333

6.  Water extract of Uncaria sinensis suppresses RANKL-induced bone loss by attenuating osteoclast differentiation and bone resorption.

Authors:  Hyunil Ha; Ki-Shuk Shim; Jin Yeul Ma
Journal:  Integr Med Res       Date:  2017-09-20

7.  Dihydromyricetin Protects against Bone Loss in Ovariectomized Mice by Suppressing Osteoclast Activity.

Authors:  Libo Zhao; Cong Cai; Jing Wang; Liming Zhao; Weijin Li; Changyu Liu; Hanfeng Guan; Yuanli Zhu; Jun Xiao
Journal:  Front Pharmacol       Date:  2017-12-19       Impact factor: 5.810

8.  The effects of downhill and uphill exercise training on osteogenesis-related factors in ovariectomy-induced bone loss.

Authors:  Yun-Seok Kang; Chun-Ho Kim; Jeong-Seok Kim
Journal:  J Exerc Nutrition Biochem       Date:  2017-09-30

9.  Water Extract of Dryopteris crassirhizoma Attenuates Bone Loss by Suppressing Osteoclast Differentiation and Function.

Authors:  Hyunil Ha; Ki-Shuk Shim; Taesoo Kim; Hyosun An; Jin Yeul Ma
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-20       Impact factor: 2.629

10.  Cytoplasmic hnRNPK interacts with GSK3β and is essential for the osteoclast differentiation.

Authors:  Xiaoqin Fan; Haiting Xiong; Jinmei Wei; Xuejuan Gao; Yuan Feng; Xiaohui Liu; Gong Zhang; Qing-Yu He; Jiake Xu; Langxia Liu
Journal:  Sci Rep       Date:  2015-12-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.